Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Reminds Unicycive Therapeutics, Inc. Investors with Large Losses to Contact the Firm Seeking Lead Plaintiff Role

Performance

52-Week Range 52.6% below 52-week high

4.140

3.9352W Low 8.7452W High

1 Week 10.4% below 1-week high

4.031W Low 4.621W High

Unicycive Therapeutics, Inc. - Common Stock (UNCY) traded between $3.93 and $8.74 over the past 52 weeks and last traded at $4.14, 52.6% below its 52-week high. Over the past week it ranged between $4.03 and $4.62.

Past 12 Months

-1.9%

-17.7%

-21.3%

-37.7%

-28.6%

-13.2%

1W -$0.08

1M -$0.89

3M -$1.12

6M -$2.51

YTD -$1.66

1Y -$0.63

UNCY was -13.2% over the past year, -37.7% over six months, -28.6% year to date, -1.9% in the last week.

12 Months vs Market

UNCY

-13.2%

DIA

+10.6%

SPY

+15.6%

QQQ

+22.8%

IWM

+13.1%

Over the past 12 months UNCY returned -13.2% versus DIA (Dow) +10.6%, SPY (S&P 500) +15.6%, QQQ (Nasdaq 100) +22.8% and IWM (Russell 2000) +13.1%.

Volume & Liquidity 0.28× 3-mo avg

Today 235,588 3-mo avg 842.2K

948.8K

940.5K

842.2K

1.1M

YTD

925.2K

805.7K

UNCY most recently traded 235,588 shares against a 3-month average daily volume of 842.2K.

More News

October 08, 2026

From Bragar Eagel & Squire

UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 07, 2026

From Faruqi & Faruqi LLP

UNCY Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Securities Class Action Against Unicycive Therapeutics, Inc.

October 05, 2026

Via Newsfile

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY

October 02, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

Kaplan Fox Class Action Reminder: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Lead Plaintiff Deadline is November 2, 2026

October 02, 2026

Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit Against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is November 2, 2026

Unicycive Therapeutics Appoints Meredith Manning to Board of Directors

October 01, 2026

Via B2i Digital

September 30, 2026

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

September 29, 2026

Via B2i Digital

Kaplan Fox Deadline Alert: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors Have Until November 2, 2026 to Seek a Lead Plaintiff Role

September 28, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 25, 2026

From The Rosen Law Firm PA

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026

September 24, 2026

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026

September 22, 2026

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

September 22, 2026

From Schall, Brown & Schwartz LLP

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

September 18, 2026

From Robbins LLP

Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm Before Lead Plaintiff Deadline on November 2, 2026

September 18, 2026

Kaplan Fox Reminds Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to a Securities Class Action Deadline - Contact the Firm Before November 2, 2026

September 16, 2026

Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies

September 15, 2026

Via Newsfile

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

September 15, 2026

From Schall, Brown & Schwartz LLP

UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. and Encourages Investors to Contact the Firm

September 14, 2026

From Bragar Eagel & Squire

Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY

September 11, 2026

From Levi & Korsinsky, LLP

UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

September 10, 2026

From Kirby McInerney LLP

Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm to Learn About Their Legal Rights

September 10, 2026

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

September 09, 2026

From Glancy Prongay Wolke & Rotter LLP